Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Equity Average: 2014-2025

Historic Equity Average for Ocular Therapeutix (OCUL) over the last 11 years, with Sep 2025 value amounting to $282.1 million.

  • Ocular Therapeutix's Equity Average fell 22.69% to $282.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.1 million, marking a year-over-year decrease of 22.69%. This contributed to the annual value of $203.2 million for FY2024, which is 221.30% up from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's Equity Average is $282.1 million, which was down 1.35% from $285.9 million recorded in Q2 2025.
  • Ocular Therapeutix's 5-year Equity Average high stood at $392.8 million for Q2 2024, and its period low was $5.5 million during Q3 2023.
  • Its 3-year average for Equity Average is $207.6 million, with a median of $282.1 million in 2025.
  • In the last 5 years, Ocular Therapeutix's Equity Average surged by 13,659.20% in 2021 and then tumbled by 91.21% in 2023.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Equity Average stood at $87.7 million in 2021, then crashed by 53.46% to $40.8 million in 2022, then rose by 21.29% to $49.5 million in 2023, then skyrocketed by 574.22% to $333.7 million in 2024, then fell by 22.69% to $282.1 million in 2025.
  • Its Equity Average was $282.1 million in Q3 2025, compared to $285.9 million in Q2 2025 and $290.6 million in Q1 2025.